[1] Ramteke A, Lamture Y. Tics and Tourette syndrome: A literature review of etiological, clinical, and pathophysiological aspects[J]. Cureus, 2022,14(8):e28575.
[2] McGuire JF, Piacentini J, Storch EA, et al. Defining tic severity and tic impairment in Tourette disorder[J]. J Psychiatr Res, 2021,133:93-100.
[3] 姜妍琳, 张蔷, 翟睿, 等. 中国儿童抽动障碍患病率及危险因素系统评价[J]. 中国儿童保健杂志, 2023,31(6):661-667.
Jiang YL,Zhang Q,Zhai R,et al. Systematic review of the prevalence and risk factors of tic Chinese children[J]. Chin J Child Health Care, 2023,31 (6): 661-667.(in Chinese)
[4] Liu ZS, Cui YH, Sun D, et al. Current Status, diagnosis, and treatment recommendation for tic disorders in China[J]. Front Psychiatry, 2020,11:774.
[5] Kong L, Lv B, Wu T, et al. Altered structural cerebral cortex in children with Tourette syndrome[J]. Eur J Radiol, 2020,129:109119.
[6] Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: Functions, signaling, and association with neurological diseases[J]. Cell Mol Neurobiol, 2019,39(1):31-59.
[7] Davis SE, Cirincione AB, Jimenez-Torres AC, et al. The impact of neurotransmitters on the neurobiology of neurodegenerative diseases[J]. Int J Mol Sci, 2023,24(20):15340.
[8] Misganaw D. Heteromerization of dopaminergic receptors in the brain: pharmacological implications[J]. Pharmacol Res, 2021,170:105600.
[9] Speranza L, di Porzio U, Viggiano D, et al. Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control[J]. Cells, 2021,10(4):735.
[10] Felsing DE, Jain MK, Allen JA. Advances in dopamine D₁ receptor ligands for neurotherapeutics[J]. Curr Top Med Chem, 2019,19(16):1365-1380.
[11] Martel JC, Gatti McArthur S. Dopamine receptor subtypes, physiology and pharmacology: New ligands and concepts in schizophrenia[J]. Front Pharmacol, 2020,11:1003.
[12] Buse J, Schoenefeld K, Munchau A, et al. Neuromodulation in Tourette syndrome: Dopamine and beyond[J]. Neurosci Biobehav Rev, 2013,37(6):1069-1084.
[13] Maia TV, Conceição VA. Dopaminergic disturbances in Tourette syndrome: An integrative account[J]. Biol Psychiatry. 2018,84(5):332-344.
[14] Terao Y, Nomura Y, Fukuda H, et al. The pathophysiology of Gilles de la Tourette Syndrome: Changes in saccade performance by low-dose L-Dopa and dopamine receptor blockers[J]. Brain Sci, 2023,13(12):1634.
[15] Maia TV, Conceição VA. The roles of phasic and tonic dopamine in tic learning and expression[J]. Biol Psychiatry, 2017,82(6):401-412.
[16] Ernst M, Zametkin AJ, Jons PH, et al. High presynaptic dopaminergic activity in children with Tourette′s disorder[J]. J Am Acad Child Adolesc Psychiatry, 1999,38(1):86-94.
[17] Cheon KA, Ryu YH, Namkoong K, et al. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette′s disorder[J]. Psychiatry Res, 2004,130(1):85-95.
[18] Iverson AM, Black KJ. Why tic severity changes from then to now and from here to there[J]. J Clin Med, 2022,11(19):5930.
[19] Tan CY, Chiu N, Zeng Y, et al. Psychosocial stress in children with Tourette syndrome and chronic tic disorder[J]. Pediatr Neonatol, 2023,S1875-9572(23)00210-3.
[20] Lamanna J, Ferro M, Spadini S, et al. The dysfunctional mechanisms throwing tics: structural and functional changes in Tourette syndrome[J]. Behav Sci (Basel), 2023,13(8):668.
[21] Hsu CJ, Wong LC, Lee WT. Immunological dysfunction in Tourette syndrome and related disorders[J]. Int J Mol Sci, 2021,22(2):853.
[22] Schrag A, Martino D, Apter A, et al. European Multicentre Tics in Children Studies (EMTICS): Protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents[J]. Eur Child Adolesc Psychiatry, 2019,28(1):91-109.
[23] Wang HC, Lau CI, Lin CC, et al. Group a streptococcal infections are associated with increased risk of pediatric neuropsychiatric disorders: A Taiwanese population-based cohort study[J]. J Clin Psychiatry, 2016,77(7):e848-e854.
[24] Roessner V, Eichele H, Stern JS, et al. European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part Ⅲ: pharmacological treatment[J]. Eur Child Adolesc Psychiatry, 2022,31(3):425-441.
[25] Doobay M, Sharma V, Eccles H. Antiseizure medication-induced obsessive-compulsive disorder and tic disorder: A pragmatic review[J]. Expert Rev Neurother, 2022,22(8):721-731.
[26] 孙云云, 韩斐, 杨晴晴, 等. 共患和不共患ADHD的抽动障碍患儿临床特征调查分析[J]. 中国儿童保健杂志, 2021,29(1):97-100,105.
Sun YY, Han F, Yang QQ, et al. Iclinical investigation analysis of tic disorder in children with and without attention defict hyperactivity dsiorder[J]. Chin J Child Health Care, 2021,29 (1): 97-100,105.(in Chinese)
[27] Rothenberger A, Heinrich H. Co-occurrence of tic disorders and attention-deficit/hyperactivity disorder-does it reflect a common neurobiological background?[J]. Biomedicines, 2022,10(11):2950.
[28] Kumar A, Trescher W, Byler D. Tourette syndrome and comorbid neuropsychiatric conditions[J]. Curr Dev Disord Rep, 2016,3(4):217-221.
[29] Cox JH, Cavanna AE. Aripiprazole for the treatment of Tourette syndrome[J]. Expert Rev Neurother, 2021,21(4):381-391.
[30] 辛莹莹, 石亮, 梅艳,等. 阿立哌唑治疗抽动障碍的药动学研究进展[J]. 药物流行病学杂志, 2023,32(2):221-226.
Xin YY, Shi L, Mei Y, et al. Progress of the pharmacokinetics for aripiprazole in the treatment of tic disorder[J]. Chin J Pharmacoepidemiol, 2023,32(2): 221-226.(in Chinese)
[31] 李丽嫱, 陈娜, 高宝勤, 等. 硫必利联合羚羊角胶囊治疗儿童抽动秽语综合征[J]. 长春中医药大学学报, 2019,35(3):476-479.
Li LQ, Chen N, Gao BQ, et al. Effect and mechanism of tiapride combined with lingyangjiao capsule in the treatment of Tourette syndrome in children[J]. J Changchun Univ Tradit Chin Med, 2019,35(3): 476-479.(in Chinese)
[32] 卢青, 孙丹, 刘智胜. 中国抽动障碍诊断和治疗专家共识解读[J]. 中华实用儿科临床杂志, 2021,36(9):647-653.
Lu Q, Sun D, Liu ZS. Interpretation expert consensus for diagnosis and treatment of tic disorder in China[J]. Chin J Appl Clin Pediatr, 2021,36 (9): 647-653.(in Chinese)
[33] Mogwitz S, Buse J, Wolff N, et al. Update on the pharmacological treatment of tics with dopamine-modulating agents[J]. ACS Chem Neurosci, 2018,9(4):651-672.
[34] Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome[J]. CNS Drugs, 2018,32(1):33-45.
[35] Gilbert DL, Murphy TK, Jankovic J, et al. Ecopipam, a D₁ receptor antagonist, for treatment of Tourette syndrome in children: A randomized, placebo-controlled crossover study[J]. Mov Disord, 2018,33(8):1272-1280.
[36] Gilbert DL, Dubow JS, Cunniff TM, et al. Ecopipam for Tourette syndrome: A randomized trial[J]. Pediatrics, 2023,151(2):e2022059574.